Opinion|Videos|November 21, 2024
Anticipating Advances for Pediatric Vitiligo
Author(s)Lisa Swanson, MD, FAAD
Key Takeaways
- Targeted biologics and JAK inhibitors show promise in modulating immune responses and promoting repigmentation in pediatric vitiligo.
- Advancements in phototherapy and laser treatments offer improved efficacy and safety profiles for children with vitiligo.
The panelist discusses advances in targeted therapies, including novel biologics and small molecules, as well as the development of personalized treatment approaches tailored to individual patient characteristics, which hold great promise for improving outcomes and enhancing the quality of life for children living with vitiligo in the future.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What advances in research or new therapies do you believe hold the most promise for improving outcomes in pediatric vitiligo treatment?
- How do you envision the future of vitiligo management for children, particularly in the context of personalized medicine and innovative treatment strategies?
Advertisement
Related to this article
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
Dermatology clinicians at a Case-Based Roundtable in Austin, Texas, discussed real-world strategies for sequencing topical therapy, phototherapy, and ruxolitinib cream across pediatric and adult vitiligo cases.
Advertisement
Advertisement
Trending on Dermatology Times
1
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
2
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
3
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
4
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
5